From GlobeNewswire: 2025-01-07 09:00:00

T2 Biosystems, Inc. announced unaudited financial results for Q4 2024 and full year 2024. Record product revenues of $2.3 million for Q4 and $8.3 million for the full year were driven by sepsis test sales. The company also signed a U.S. agreement with Cardinal Health and expanded its international distribution network.

In 2024, T2 Biosystems achieved milestones in its pipeline and clinical efforts. FDA clearances were received to expand pathogen detection capabilities of the T2Bacteria Panel and T2Candida Panel. The company also advanced the T2Resistance Panel towards FDA submission and successfully defended a key patent in the EU.

T2 Biosystems’ CEO, John Sperzel, highlighted progress made in 2024, including record sales and FDA clearances. The company also entered into an exclusive U.S. commercial distribution agreement with Cardinal Health. Looking ahead to 2025, T2 Biosystems aims to accelerate product sales and advance its pipeline, which includes FDA Breakthrough Device designated products.

T2 Biosystems, a leader in rapid sepsis detection, is dedicated to improving patient care with innovative technologies. Their products, including the T2Dx Instrument and various panels, utilize T2MR technology. The company is focused on expanding its product offerings and enhancing patient outcomes through early detection of pathogens.



Read more at GlobeNewswire:: T2 Biosystems Announces Preliminary Fourth Quarter and Full